J&J nabs an early OK for ‘breakthrough’ multiple myeloma blockbuster contender Darzalex

John Carroll

Johnson & Johnson scored an FDA approval for its "breakthrough" daratumumab, earning a swift OK as a new treatment for four months ahead of the PDUFA date. The drug will be marketed as .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS